Stockreport

New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficu...

Syros Pharmaceuticals, Inc.  (SYRS) 
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am Check Earnings Report
US:NASDAQ Investor Relations: ir.syros.com
PDF SY-1365 Currently in Phase 1 Clinical Trial in Relapsed and Treatment-Resistant Ovarian and Breast Cancer Patients CAMBRIDGE, Mass.--(BUSINESS WIRE [Read more]